Fofana MO - Search Results

1

Time and time again: the reincarnations of coerced sterilisation.

Fofana MO. Fofana MO. J Med Ethics. 2022 Nov;48(11):805-809. doi: 10.1136/medethics-2020-106924. Epub 2021 Jun 14. J Med Ethics. 2022. PMID: 34127527

2

Decolonising global health in the time of COVID-19.

Fofana MO. Fofana MO. Glob Public Health. 2021 Aug-Sep;16(8-9):1155-1166. doi: 10.1080/17441692.2020.1864754. Epub 2020 Dec 28. Glob Public Health. 2021. PMID: 33370211

3

Scaling up antiretroviral therapy in South Africa: the impact of speed on survival.

Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA; CEPAC-International Investigators. Walensky RP, et al. Among authors: fofana mo. J Infect Dis. 2008 May 1;197(9):1324-32. doi: 10.1086/587184. J Infect Dis. 2008. PMID: 18422445 Free PMC article.

4

Cost-effectiveness of novel first-line treatment regimens for tuberculosis.

Owens JP, Fofana MO, Dowdy DW. Owens JP, et al. Among authors: fofana mo. Int J Tuberc Lung Dis. 2013 May;17(5):590-6. doi: 10.5588/ijtld.12.0776. Int J Tuberc Lung Dis. 2013. PMID: 23575322 Free PMC article.

5

Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.

Fofana MO, Knight GM, Gomez GB, White RG, Dowdy DW. Fofana MO, et al. PLoS One. 2014 May 9;9(5):e96389. doi: 10.1371/journal.pone.0096389. eCollection 2014. PLoS One. 2014. PMID: 24816692 Free PMC article.

6

Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis.

Shrestha S, Knight GM, Fofana M, Cohen T, White RG, Cobelens F, Dowdy DW. Shrestha S, et al. Open Forum Infect Dis. 2014 Aug 30;1(2):ofu073. doi: 10.1093/ofid/ofu073. eCollection 2014 Sep. Open Forum Infect Dis. 2014. PMID: 25734143 Free PMC article.

7

Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.

Kendall EA, Fofana MO, Dowdy DW. Kendall EA, et al. Among authors: fofana mo. Lancet Respir Med. 2015 Dec;3(12):963-72. doi: 10.1016/S2213-2600(15)00458-0. Epub 2015 Nov 18. Lancet Respir Med. 2015. PMID: 26597127 Free PMC article.

8

A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.

Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW. Fofana MO, et al. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e00498-16. doi: 10.1128/AAC.00498-16. Print 2017 Mar. Antimicrob Agents Chemother. 2017. PMID: 27956422 Free PMC article.

9

Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment".

Fofana MO, Dowdy DW. Fofana MO, et al. Antimicrob Agents Chemother. 2017 May 24;61(6):e00427-17. doi: 10.1128/AAC.00427-17. Print 2017 Jun. Antimicrob Agents Chemother. 2017. PMID: 28539499 Free PMC article. No abstract available.

10

The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis.

Knight GM, Colijn C, Shrestha S, Fofana M, Cobelens F, White RG, Dowdy DW, Cohen T. Knight GM, et al. Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S147-54. doi: 10.1093/cid/civ579. Clin Infect Dis. 2015. PMID: 26409276 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page